NOTE 15 – STOCK WARRANTS

The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company at December 31, 2024:

During the year ended December 31, 2024, 113,155 prefunded common warrants were exercised.

For the year ended December 31, 2024, 36 and 1 warrants with an exercise price of $1,600.00 and $320,000.00, respectively, expired.

For the year ended December 31, 2024, 8,700 and 8,700 warrants with an exercise price of $1,776.00 and $2,720.00, respectively, were returned and cancelled.

Subsequent to December 31, 2024, 10,884, 5,758 (as the Company received FDA acceptance of our NDA filing), and 1 warrants with an exercise price of $1,056.00, $1,776.00 and $364,800.00, respectively, expired.

Additionally, with the closing of the financing on April 1, 2024, the Company entered into the Warrant Amendments (as defined in Note 13) with certain holders of its warrants to purchase common stock, agreeing to amend the exercise price of each Existing Warrant to $1,056.00 upon approval by the Company’s stockholders of a proposal to allow the warrants to become exercisable in accordance with Nasdaq Listing Rule 5635 or, if stockholder approval is not obtained by October 1, 2024, the exercise price would be automatically amended to the Minimum Price (as defined in Nasdaq Listing Rule 5635(d)) of the Company’s common stock on October 1, 2024, if and only if the Minimum Price is below the then current exercise price. The Company’s stockholders approved the proposal to amend the exercise prices of the Existing Warrants to $1,056.00 per share and extend the termination dates at the annual meeting of the Company’s stockholders held on May 22, 2024. As such, the table above reflects the modified terms of the Existing Warrants in effect as of December 31, 2024. See Note 13 for further details.

No common warrants were exercised during the year ended December 31, 2023.

For the year ended December 31, 2023, 1 warrant with an exercise price of $22,400,000.00 expired.